{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:19:25Z","timestamp":1789654765165,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40262-023-01316-5","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T13:02:54Z","timestamp":1697720574000},"page":"1749-1754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-4740","authenticated-orcid":false,"given":"Leila S.","family":"Otten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demy","family":"van den Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou","family":"Schuurbiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil K.","family":"Badrising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Boerrigter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjaak A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"crossref","unstructured":"Miao K, Zhang X, Wang H, Si X, Ni J, Zhong W, et al. Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China. Front Oncol. 2022;12:859938.","DOI":"10.3389\/fonc.2022.859938"},{"key":"1316_CR2","doi-asserted-by":"crossref","unstructured":"Humbert O, Chardin D. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol. 2020;10:566297.","DOI":"10.3389\/fonc.2020.566297"},{"issue":"5","key":"1316_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cpt.656","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yu J, Li H, Liu J, Xu Y, Song P, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101(5):657\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1316_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44(5):403\u201314.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"23","key":"1316_CR5","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","volume":"24","author":"DC Turner","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, et al. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24(23):5841\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1316_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/psp4.12406","volume":"8","author":"JJ Wilkins","year":"2019","unstructured":"Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, et al. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma. CPT Pharmacomet Syst Pharmacol. 2019;8(6):415\u201327.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"1316_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1316_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1316_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/psp4.12476","volume":"8","author":"J Zhang","year":"2019","unstructured":"Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, et al. Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):962\u201370.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1316_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2046-4053-2-10","volume":"2","author":"H Wao","year":"2013","unstructured":"Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013;2(1):10.","journal-title":"Syst Rev"},{"key":"1316_CR11","unstructured":"Kassambara A, Kosinski M, Biecek P. Survminer: Drawing Survival Curves using 'ggplot2'. R package version 0.4.9. 2021. https:\/\/CRAN.R-project.org\/package=survminer."},{"key":"1316_CR12","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New York; 2016. https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"1316_CR13","unstructured":"Hothorn T. maxstat: Maximally Selected Rank Statistics. 2017. R package version 0.7-25. https:\/\/CRAN.R-project.org\/package=maxstat."},{"issue":"1","key":"1316_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","volume":"7","author":"DP Hurkmans","year":"2019","unstructured":"Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019;7(1):192.","journal-title":"J Immunother Cancer"},{"issue":"18","key":"1316_CR15","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1158\/1078-0432.CCR-16-2842","volume":"23","author":"Y Feng","year":"2017","unstructured":"Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res. 2017;23(18):5394\u2013405.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1316_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/biomedicines9060621","volume":"9","author":"A Millet","year":"2021","unstructured":"Millet A, Khoudour N, Guitton J, Lebert D, Goldwasser F, Blanchet B, et al. Analysis of pembrolizumab in human plasma by LC-MS\/HRMS. Method validation and comparison with elisa. Biomedicines. 2021;9(6):621.","journal-title":"Biomedicines."},{"issue":"5","key":"1316_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/FTD.0000000000000534","volume":"40","author":"EA Basak","year":"2018","unstructured":"Basak EA, Wijkhuijs AJM, Mathijssen RHJ, Koolen SLW, Schreurs MWJ. Development of an enzyme-linked immune sorbent assay to measure nivolumab and pembrolizumab serum concentrations. Ther Drug Monit. 2018;40(5):596\u2013601.","journal-title":"Ther Drug Monit"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","volume":"164","author":"D Pluim","year":"2019","unstructured":"Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J Pharm Biomed Anal. 2019;164:128\u201334.","journal-title":"J Pharm Biomed Anal"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.aca.2018.02.040","volume":"1019","author":"HH Chiu","year":"2018","unstructured":"Chiu HH, Liao HW, Shao YY, Lu YS, Lin CH, Tsai IL, et al. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS\/MS. Anal Chim Acta. 2018;1019:93\u2013102.","journal-title":"Anal Chim Acta"},{"issue":"6","key":"1316_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argil\u00e9s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793\u20139.","journal-title":"Clin Nutr"},{"issue":"6","key":"1316_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","volume":"83","author":"KC Fearon","year":"2006","unstructured":"Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis2. Am J Clin Nutr. 2006;83(6):1345\u201350.","journal-title":"Am J Clin Nutr"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"S448","DOI":"10.1016\/j.annonc.2022.07.1199","volume":"33","author":"APBR Puszkiel","year":"2022","unstructured":"Puszkiel APBR, Arrondeau J, Wislez M, Fabre-Guillevin E, Bianconi G, Decl\u00e8ves X, Jouinot A, De Percin S, Alexandre J, Goldwasser F, Blanchet B. 1073P - Relationship between basal metabolism, nivolumab clearance and survival in metastatic non-small cell lung cancer patients of the ELY study. Ann Oncol. 2022;33:S448\u2013554.","journal-title":"Ann Oncol"},{"key":"1316_CR23","unstructured":"U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review OPDIVO (Nivolumab). 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125554orig1s000clinpharmr.pdf."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01316-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T14:17:02Z","timestamp":1701181022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01316-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01316-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"29 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study (N13FPB) in which the subjects participated was approved by the Medical Ethics Committee of the Netherlands Cancer Institute.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"RtH, MvdH, SAB, BP and LSO conceived of the presented research idea RS, DvdH, SB and LSO collected data and samples. LSO, DvdH and EB took the lead in designing the analysis, LSO performed the analysis. MS, RtH, BP, MvdH and EB contributed to the interpretation of the results: LSO wrote the manuscript with input from all authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}